SANA Live signaler | Maksimer profitt med Getagraph.com

KJøP 105740 min ago

@ $7.22

Utstedt: 14 feb 2024 @ 21:45

Avkastning: 20.86%

Forrige signal: feb 13 - 20:34

Forrige signal: Selg

Avkastning: 12.56 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	1.59M
Gjennomsnittsvolum	2.01M
Markedsverdi	1.92B
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $-0.300 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.97
ATR14	$0.0150 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Bishop Hans Edgar	Buy	2 774	Common Stock
2024-04-01	Fmr Llc	Buy	0	Common Stock
2024-03-08	Yang Patrick Y	Sell	25 000	Common Stock
2024-03-07	Williams Douglas E	Buy	301 875	Stock Option (Right to Buy)
2024-03-07	Williams Douglas E	Buy	67 083	Restricted Stock Units

INSIDER POWER
6.23
Last 97 transactions
Buy: 15 455 910 \| Sell: 11 982 863

Volum Korrelasjon

Lang: -0.07 (neutral)

Kort: -0.29 (neutral)

Signal:(47.218) Neutral

Sana Biotechnology, Inc. Korrelasjon

10 Mest positive korrelasjoner
ALVR	0.839
MDVL	0.839
TCRT	0.836
USEG	0.834
HOOK	0.832
TLSA	0.832
GRAY	0.828
INFI	0.824
OPK	0.815
RUBY	0.815

10 Mest negative korrelasjoner
BNIXU	-0.875
MICT	-0.812

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Sana Biotechnology, Inc. Korrelasjon - Valuta/Råvare

-0.34
( neutral )

-0.61
( weak negative )

0.00
( neutral )

-0.72
( moderate negative )

-0.18
( neutral )

-0.02
( neutral )

Sana Biotechnology, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2023
Omsetning:	$0
Bruttogevinst:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2022
Omsetning:	$0
Bruttogevinst:	$-27.73M (0.00 %)
EPS:	$-1.410

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.958

Financial Reports:

No articles found.

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.